BioWorld MedTech

Sep. 22, 2016

Analysts sift through Abbott unit sale to find read-through for contested Alere deal

Abbott Laboratories' divestiture of its optics business could indicate that the company is ready to bite the figurative Alere Inc. bullet and move forward with that $5.8 billion acquisition – but not necessarily. Read More

Califf says combo products 'on my mind,' along with cross-center coordination

Spirox's Latera absorbable nasal implant technology demonstrates significant quality of life improvement

Weak clinical trial data in China leads to a rush of device withdrawals

Financings

Appointments and advancements

Product briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for March 26, 2026.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026